C-QTc and C-QT Analysis: Replacing TQT Studies and Accelerating Cardiovascular Safety Decisions
Replace or waive TQT studies with validated C-QT analysis strategies accepted by FDA, EMA, PMDA.…
CertaraOctober 3, 2025
Certara & Dizal Partner to Fast-Track FDA Approval of Sunvozertinib for Lung Cancer
Certara’s support enabled fast-track FDA oncology approval 2025 for Sunvozertinib, a breakthrough NSCLC therapy targeting…
CertaraOctober 2, 2025
Certara Launches Libra™: AI-Powered Drug-Induced Liver Injury Prediction Tool
RADNOR, Pa. – September 17, 2025 – Certara, Inc. (Nasdaq: CERT), a global leader in…
CertaraSeptember 17, 2025
Top 10 Things to Know About ADNCA for Non-Compartmental Analysis
Learn how to transition from non-standard ADPC datasets to the CDISC ADNCA ADaM standard. Improve…
CertaraSeptember 11, 2025
The Pursuit of Certainty: Integrated Evidence and the evolving drug development and reimbursement landscape
Watch leading experts from Pfizer, Merck, Amicus, and Certara discuss how Integrated Evidence can bridge…
CertaraSeptember 3, 2025
